Stereotactic body radiotherapy (SBRT) for primary liver tumors (HepReg)

Study PI:

Prof. Dr. med. Thomas Brunner
University Hospital Graz

PD Dr. med. Danny Jazmati
University Hospital Düsseldorf


Recruiting centers ( Contact Danny Jazmati for participation)

Study design:

● Multi-center, international retrospective and prospective study

Study objective:

  • To perform a patterns-of-care and patterns-of-outcome analysis of SBRT for primary liver tumors in Germany, Austria and Switzerland
  • To evaluate patient and treatment factor influencing outcome in SBRT for primary liver tumors

Project status:

  • First Round Data collection completed
  • 3 full manuscripts published
  • Second Round analysis planned

Major findings and results:

Bettinger D, Pinato DJ, Schultheiss M, et al (2019) Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer 8:281–294.

  • International retrospective matched pair analysis of patients with advanced hepatocellular carcinoma treated with SBRT or sorafenib
  • 122 patients treated with SBRT and 901 patients treated with sorafenib were compared for overall survival and progression-free survival
  • Baseline characteristics between groups were adjusted by propensity score matching
  • Median overall survival in adjusted, matched analysis:
    16.0 months SBRT group vs. 9.6 months sorafenib group (HR 0.53, p=0.005)
  • Progression-free survival in adjusted, matched analysis:
    9.0 months SBRT group vs. 6.0 months sorafenib group (HR 0.59, p=0.004)

Brunner TB, Blanck O, Lewitzki V, et al (2019) Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma. Radiotherapy and Oncology 132:42–47.

  • 64 patients with 82 non-resectable primary lesions of cholangiocarcinomas treated with SBRT were analyzed retrospectively for overall survival, local control, and toxicity
  • Median follow-up 35 months, median OS 15 months, 2-y-OS 32%, 3-y-OS 21%
  • Stat. significant prognostic factor for LC and OS in univariate analysis: biologically effective dose (BEDmax>91 Gy10)
  • BEDmax>91 Gy10: 1-y-LC 91%, 2-y-LC 80%, median OS 24 months
  • BEDmax<91 Gy10: 1-y-LC 66%, 2-y-LC 39%, median OS 13 months
  • Tumor size and PTV were neither predictive nor prognostic for LC or OS
  • Toxicity: 17% G1 gastroduodenitis, 11% G2-3 cholangitis, 4.7% G3 GI-bleeding